First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors

BACKGROUND: Vascular endothelial growth factor receptor 2 (VEGFR2) plays a key role in antiangiogenesis which has been an essential strategy for cancer treatment. We report the first-in-human study of AK109, a novel anti-VEGFR2 monoclonal antibody, to characterize the safety profile and pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Y., Zhong, H., Zhao, F., Zhou, H., Mao, C., Lv, W., Yuan, M., Qian, J., Jiang, H., Wang, Z., Xiao, C., Guo, J., Liu, T., Liu, W., Wang, Z.M., Li, B., Xia, M., Xu, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163150/
https://www.ncbi.nlm.nih.gov/pubmed/36989884
http://dx.doi.org/10.1016/j.esmoop.2023.101156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163150/
https://www.ncbi.nlm.nih.gov/pubmed/36989884
http://dx.doi.org/10.1016/j.esmoop.2023.101156

Ejemplares similares